NEUMORA THERAPEUTICS, INC.

NASDAQ: NMRA (Neumora Therapeutics, Inc.)

Last update: 10 hours ago

1.12

0.22 (24.21%)

Previous Close 0.902
Open 0.900
Volume 2,275,075
Avg. Volume (3M) 1,047,658
Market Cap 181,157,760
Price / Book 0.640
52 Weeks Range
0.611 (-45%) — 17.19 (1434%)
Earnings Date 4 Aug 2025 - 18 Aug 2025
Diluted EPS (TTM) -1.61
Total Debt/Equity (MRQ) 0.41%
Current Ratio (MRQ) 8.98
Operating Cash Flow (TTM) -199.43 M
Levered Free Cash Flow (TTM) -108.00 M
Return on Assets (TTM) -48.51%
Return on Equity (TTM) -79.05%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Neumora Therapeutics, Inc. Bearish Bearish

AIStockmoo Score

-0.1
Analyst Consensus -0.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average -0.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NMRA 181 M - - 0.640
MRNA 12 B - - 1.17
CGON 2 B - - 2.81
CVAC 1 B - 5.77 1.61
VIR 731 M - - 0.720
ZVRA 616 M - - 12.54

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 27.57%
% Held by Institutions 60.19%

Ownership

Name Date Shares Held
Softbank Group Corp. 31 Mar 2025 6,541,190
Mic Capital Management Uk Llp 31 Mar 2025 4,460,700
Siren, L.L.C. 31 Mar 2025 4,358,283
Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust 31 Mar 2025 3,309,123
Iconiq Capital, Llc 31 Mar 2025 2,559,090
Lunate Capital Ltd 31 Mar 2025 2,124,143
Lunate Holding Rsc Ltd 31 Dec 2024 2,124,143
T. Rowe Price Investment Management, Inc. 31 Mar 2025 2,103,029
Johnson & Johnson 31 Mar 2025 1,849,445
52 Weeks Range
0.611 (-45%) — 17.19 (1434%)
Median 5.00 (346.43%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Needham 13 May 2025 5.00 (346.43%) Buy 0.679
10 Apr 2025 5.00 (346.43%) Buy 0.717

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria